Clinical trial · Observational
Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV)
Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) in Patients With Hepatitis C Virus
NCT01545544CI-TRIAL-00013696Lympho CunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
An prospective / retrospective multicenter observational study whose objectives are to understand the interactions between hepatitis c virus and Non Hodgkin lymphomas. The characteristics , evolution and treatment of diseases will be observed from the study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Hepatitis C | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- presentation of NHL and HCV infection, and treatments of NHL and HCV infection
- timeFrame
- at the first visit (Day 0)
- description
- the presentation of NHL and HCV infection is done by clinical,histological and biological characteristics
Secondary outcomes (3)
- measure
- Summary of intercurrents biological and clinical events
- timeFrame
- Month 6, Month 12, Month 24, Month 36, Month 48 and Month 60
- measure
- virological response
- timeFrame
- Month 60
- description
- HCV quantitative viral load
- measure
- haematological response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with evolving NHL whatever its histological type * At diagnosis or relapse or failure previous treatments stopped over 3 months * Patients with HCV infection with positive quantitative viral load * 18 years or more of age * Life expectancy greater than 6 months * Signed and informed consent * Benefit from social security Exclusion Criteria: * Active uncontrolled infection (out hepatitis C) * HIV (Human immunodeficiency virus) infection * Severe psychiatric history
References
Publications (1)
- DERIVEDMichot JM, Canioni D, Driss H, Alric L, Cacoub P, Suarez F, Sibon D, Thieblemont C, Dupuis J, Terrier B, Feray C, Tilly H, Pol S, Leblond V, Settegrana C, Rabiega P, Barthe Y, Hendel-Chavez H, Nguyen-Khac F, Merle-Beral H, Berger F, Molina T, Charlotte F, Carrat F, Davi F, Hermine O, Besson C; ANRS HC-13 Lympho-C Study Group. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol. 2015 Mar;90(3):197-203. doi: 10.1002/ajh.23889. Epub 2014 Nov 24. PMID 25417909